NRx Pharmaceuticals (NRXP) Financials

NRx Pharmaceuticals’ Q2 2026 statements show a sharp increase in liquidity, but the improvement was driven primarily by equity financing rather than business operations. Cash and equivalents rose to $26.7 million from $6.7 million in Q1 2026, largely because the company issued $29.1 million of common equity. However, operating activities consumed $8.9 million during the quarter, while revenue was only $6,000.

• Liquidity improved significantly. Cash increased by $20.0 million sequentially to $26.7 million, providing more funding for near-term operations than the company had at the end of Q1.
• Balance-sheet equity nearly returned to break-even. Total equity improved to negative $170,000 in Q2 2026 from negative $13.8 million in Q1 and negative $25.8 million in Q3 2025, reflecting substantial equity financing and other balance-sheet changes.
• Interest income is gradually increasing. Investment securities interest income rose from $2,000 in Q3 2025 to $5,000 in Q1 2026 and $6,000 in Q2 2026, although it remains immaterial to the company’s overall financial position.
• Non-cash adjustments materially affected cash flow. Q2 included $10.9 million of non-cash adjustments that reduced the gap between the $16.5 million net loss and the $8.9 million operating cash burn. Investors should determine whether these adjustments are recurring before treating the cash-flow trend as an improvement.
• Investing activity remained limited. The company used $684,000 for investing activities in Q2 2026, compared with $213,000 in Q1. This spending was modest relative to the financing proceeds and cash balance.
• Revenue remains effectively nonexistent. Q2 2026 revenue was just $6,000, up slightly from $5,000 in Q1 but far below the $5.4 million reported in Q3 2025, when revenue included $5.4 million of investment gains. NRx does not yet demonstrate a consistent operating revenue base.
• Net losses worsened sharply. The Q2 2026 net loss was $16.5 million, compared with a $1.4 million loss in Q1 and a $5.9 million loss in Q3 2025. The deterioration was primarily caused by a $10.0 million net nonoperating expense.
• Operating expenses increased sequentially. Total non-interest expense rose to $6.5 million in Q2 from $4.7 million in Q1. Marketing expense increased to $2.1 million, while other operating expenses climbed to $5.4 million before special-charge offsets.
• Operating cash burn accelerated. Cash used in operations reached $8.9 million in Q2 2026, compared with $4.3 million in Q1 and $2.9 million in Q3 2025. At the Q2 burn rate, the $26.7 million cash balance would provide only several quarters of funding if no additional capital were raised and spending remained unchanged.
• NRx remains dependent on external capital and has negative equity. Q2 financing generated $29.5 million, almost entirely from common-stock issuance, while total liabilities of $34.3 million slightly exceeded total assets of $34.2 million. The company also reported negative retained earnings of $324.8 million, and weighted-average basic shares rose to 37.6 million from 32.3 million in Q1, indicating meaningful dilution risk.

Overall, NRx’s financial condition improved from a liquidity perspective during Q2 2026, but the improvement came with substantial shareholder dilution and did not reflect stronger operating performance. Persistent losses, negative equity, minimal revenue and rising cash burn remain significant risks for investors.